SEOUL — November 13, 2026 -- Classys Inc. (KOSDAQ: 214150) reported nine-month 2026 revenue of KRW 275.7 billion, up 13% year over year, while operating profit fell 9.4% to KRW 108.1 billion. By FairsOnline's calculation, the operating margin fell to about 39.2% from roughly 49% a year earlier, a drop of about 10 percentage points. The prior-year figures are implied by the reported growth rates, which the company rounds to whole or one-decimal percentages.
Third-quarter revenue was KRW 83.0 billion, roughly flat year over year. Operating profit was KRW 27.0 billion, a margin of 32.5%. Subtracting the third quarter from the nine-month totals gives first-half revenue of about KRW 192.7 billion and operating profit of about KRW 81.1 billion, a margin of about 42.1%. Third-quarter revenue ran about 14% below the first-half quarterly average of KRW 96.4 billion. Third-quarter operating profit was about a third below the first-half average of KRW 40.6 billion.
Korean product transition and direct-operations costs cut third-quarter profit
Classys attributes the pressure to lower sales in Korea as its core products entered a generational transition, and to the shift of LATAM and Japan to direct operations. In LATAM, the company incurred initial costs to normalize operations at its direct-operations subsidiary. Distribution margin on the sell-through of inventory held before it acquired Medsystems, now Classys Brasil, was limited. In Japan, upfront investment for the transition also weighed on profit. The company did not quantify these costs.
Classys describes the costs as temporary and expects the pressure to ease gradually. CEO Jun-oh Yoon cited "a weak domestic market and profitability pressure at our overseas direct-operations subsidiaries" in the quarter.
Classys expects China approval of Volnewmer in December
The company expects its first product approval in China for Volnewmer in December 2026. It is in discussions with prospective large local partners on distribution agreements. It expects Ultraformer, sold as Shurink in Korea, to be approved in the first half of 2027 and the new product Viclara in the second half of 2027. Classys says China now requires formal regulatory approval and that demand is concentrated in newly approved devices.
Classys plans a staged product rollout in the U.S. and Europe
In the U.S., Classys sells mainly Everesse, the U.S. name for Volnewmer, and the new product Quadessy. It plans to introduce Viclara, Reepot and Ultraformer in sequence to the customer base built with Everesse. In Europe, the company points to business models confirmed in Spain and Turkey. It plans to sell Ultraformer, Volnewmer, Quadessy, Viclara and Veloce there, a lineup it says is broader than its competitors'.
Korea gets new launches while LATAM and Japan work through integration
In Korea, Classys has begun full-scale marketing of Fortra, a four-wavelength laser device. In the first half of 2027 it plans to introduce a new procedure protocol and a new Volnewmer tip. It also plans a HIFU product with higher output than the existing Shurink Universe, without giving a date.
At the LATAM subsidiary, the company expects a normal margin structure once the pre-acquisition inventory has sold through. It plans to cross-sell Volnewmer, Quadessy and laser products to Ultraformer customers. In Japan, it plans to expand its customer base around large clinic chains and accelerate sales of Volnewmer and Quadessy.
Yoon said the company has added Vice President and Chief Commercial Officer Jung-hee Bae and Chief Technology Officer Dr. Taek-Soo Kim. Cumulative global unit sales passed 50,000 as of October 2026.